BridgeBio Pharma, Inc. (BBIO) stock

BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 3/30

$78.30+0.13 (+0.17%)

Close on Nov 13, 2026Market cap $15.25BP/E –Yield –

BridgeBio Pharma price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

BridgeBio Pharma's price to book ratio was 118.6× on Apr 30, 2021, against 9.2× a year earlier.

Period	Period end	Value	Change (pts)
2021	Apr 30, 2021	118.6×	+65.4
2020	Dec 31, 2020	53.2×	+44.3
2019	Dec 31, 2019	8.9×	–

Parsed from the XBRL in BridgeBio Pharma's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BBIO.

Revenue growth167.3% · median -0.7%

Gross margin94.3% · median 90.2%

Operating margin-38.5% · median -2.5%

Advertisement
300 × 250

See a number that looks wrong?